Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$235.32 USD

235.32
1,792,592

+8.44 (3.72%)

Updated May 15, 2024 04:00 PM ET

Pre-Market: $233.76 -1.56 (-0.66%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BIIB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Biogen Inc. [BIIB]

Reports for Purchase

Showing records 261 - 280 ( 799 total )

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 261

11/19/2021

Industry Report

Pages: 23

Weekly Neurology Prescription Sales Tracker -- Week Ending 11/12/21

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 262

11/17/2021

Daily Note

Pages: 4

EMA''s CHMP Says No Thanks to Aduhelm - Negative Vote From CHMP

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 5.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 263

11/15/2021

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 264

11/15/2021

Industry Report

Pages: 7

Catching The Next Wave of Innovation: Highlights from Vitreoretinal KOL Call

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 12.50

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 265

11/01/2021

Industry Report

Pages: 17

Monthly Check-Up: November 2021

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 266

10/29/2021

Industry Report

Pages: 23

Weekly Neurology Prescription Sales Tracker - Week Ending 10/22/21

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 267

10/25/2021

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 268

10/22/2021

Industry Report

Pages: 23

Weekly Neurology Prescription Sales Tracker - Week Ending 10/15/21

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 269

10/21/2021

Company Report

Pages: 7

Insights on Aduhelm Coverage, BAN2401 and Tofersen; Reit Buy and $452 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 270

10/20/2021

Daily Note

Pages: 4

3Q21 First Take: Beat/Raise But Aduhelm''s Absence Unlikely to Quell Debate

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 5.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 271

10/20/2021

Company Report

Pages: 11

New Quarter, Same Concerns - Stuck on Repeat

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 272

10/15/2021

Industry Report

Pages: 23

Biotechnology-Weekly Neurology Prescription Sales Tracker

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 273

10/05/2021

Daily Note

Pages: 6

What Can We Learn From NfL as a Biomarker in Neuro Trials? ¯Implications for Biogen''s Upcoming Phase 3 ALS Trial Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 274

10/05/2021

Daily Note

Pages: 31

3Q21 Commercial Biotech Preview: Will We See Tricks or Treats in 3Q21 Earnings?

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 275

10/04/2021

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 276

10/01/2021

Daily Note

Pages: 23

Weekly Neurology Prescription Sales Tracker -- Week Ending 9/24/21

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 277

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BIIB

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 278

09/24/2021

Daily Note

Pages: 23

Weekly Neurology Prescription Sales Tracker - Week Ending 9/17/21

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 279

09/23/2021

Company Report

Pages: 22

Biogen''s Neurodegenerative Pipeline at a Glance¯Key Takeaways from R&D Day

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 75.00

Research Provided by a Third Party

Company: Biogen Inc.

Industry: Medical - Biomedical and Genetics

Record: 280

09/22/2021

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party